merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>FDA-approved, safer alternative to compounded drugs</answer>
<question_number>2</question_number>
<answer>Direct-to-consumer sales through LillyDirect</answer>
<question_number>3</question_number>
<answer>Lack of safety, quality, and effectiveness control</answer>
<question_number>4</question_number>
<answer>Regain market share from compounded drugs</answer>
<question_number>5</question_number>
<answer>Allows compounding of shortage-listed drugs</answer>
<question_number>6</question_number>
<answer>Bypassing third-party supply chain for more competitive pricing</answer>
<question_number>7</question_number>
<answer>Appeal to uninsured Medicare patients</answer>
<question_number>8</question_number>
<answer>Enhanced safety perceptions</answer>
<question_number>9</question_number>
<answer>In shortage</answer>
<question_number>10</question_number>
<answer>Offering lower-priced FDA-approved vials</answer>